Free Trial
NASDAQ:COGT

Cogent Biosciences Q1 2025 Earnings Report

Cogent Biosciences logo
$11.40 -0.02 (-0.18%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$11.90 +0.50 (+4.43%)
As of 08/1/2025 05:07 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cogent Biosciences EPS Results

Actual EPS
-$0.52
Consensus EPS
-$0.56
Beat/Miss
Beat by +$0.04
One Year Ago EPS
N/A

Cogent Biosciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Cogent Biosciences Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Tuesday, May 6, 2025
Conference Call Time
8:00AM ET

Upcoming Earnings

Cogent Biosciences' Q2 2025 earnings is scheduled for Tuesday, August 5, 2025, with a conference call scheduled at 8:15 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Cogent Biosciences Earnings Headlines

Needham Reaffirms Their Hold Rating on Cogent Biosciences (COGT)
Scotiabank Sticks to Its Buy Rating for Cogent Biosciences (COGT)
This Crypto Is Set to Explode in January
This Could Be the Most Important Crypto Law in History While the world celebrates Bitcoin becoming 2025’s top-performing asset, smart hedge funds are accumulating elsewhere. During the upcoming Crypto Hedge Fund Summit, you'll discover exactly which coins they’ve loaded up on before this historic vote.
See More Cogent Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cogent Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cogent Biosciences and other key companies, straight to your email.

About Cogent Biosciences

Cogent Biosciences (NASDAQ:COGT), a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

View Cogent Biosciences Profile

More Earnings Resources from MarketBeat